Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac. - Archive ouverte HAL Access content directly
Journal Articles Vaccine Year : 2012

Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac.

(1, 2) , (1, 2) , (3) , (4) , (1) , (4) , (3, 5) , (4)
1
2
3
4
5

Abstract

A meningococcal B:14:P1.7,16 outbreak in Normandy (France) was recently controlled using MenBvac, an outer membrane vesicle vaccine previously designed against the B:15:P1.7,16 strain. The further emergence of a new B:14:P1.7,16 outbreak in another district in Normandy led us to explore immunity against B:14:P1.7,16 before and after the MenBvac campaign using a 2+1 (day 0, week 6, month 8) schedule. Children (1-5 years) were sampled before, during and up to one year after vaccination. Serum bactericidal activity against B:14:P1.7,16 was titrated using human complement (hSBA) and immune response was defined by hSBA titer ≥4 as a surrogate for protection. The percentage of hSBA titer ≥4 was 10.8% before vaccination, raised to 84.1% 6 weeks after the completion of the schedule, but declined to 39.7% one year later. This level is lower than the targeted 60% level and suggests only short-term persistence of response against B:14:P1.7,16 using this schedule.
Not file

Dates and versions

pasteur-02085547 , version 1 (30-03-2019)

Identifiers

Cite

Francois Caron, Valérie Delbos, Estelle Houivet, Ala-Eddine Deghmane, Jean-Philippe Leroy, et al.. Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac.. Vaccine, 2012, 30 (34), pp.5059-5062. ⟨10.1016/j.vaccine.2012.05.051⟩. ⟨pasteur-02085547⟩
50 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More